An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology

Cell Discovery

Volumn 2, Issue , 2016, Pages

  Gingell, Joseph J ^a,b   Simms, John ^c   Barwell, James ^c   Poyner, David R ^c   Watkins, Harriet A ^a,b   Pioszak, Augen A ^d   Sexton, Patrick M ^e   Hay, Debbie L ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c ASTON UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^e MONASH UNIVERSITY   (Australia)

Author keywords

accessory protein; Amylin; CGRP; G protein coupled receptor; RAMP

Indexed keywords

AMYLIN; C PEPTIDE; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; RECEPTOR; RECEPTOR ACTIVITY MODIFYING PROTEIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 3;

ALLOSTERISM; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CAMP ASSAY; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CRYSTAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 85018030657     PISSN: None     EISSN: 20565968     Source Type: Journal    
DOI: 10.1038/celldisc.2016.12     Document Type: Article

References (49)

1. Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008; 7: 339-357.
2. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010; 62: 265-304.
3. McLatchie LM, Fraser NJ, Main MJ et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393: 333-339.
4. Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL. Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov Today 2009; 14: 413-419.
5. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Therapeut 2006; 109: 173-197.
6. Harikumar KG, Simms J, Christopoulos G, Sexton PM, Miller LJ. Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor. Biochemistry 2009; 48: 11773-11785.
7. Christopoulos G, Perry KJ, MorfisMet al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 1999; 56: 235-242.
8. Christopoulos A, Christopoulos G, Morfis M et al. Novel receptor partners and function of receptor activitymodifying proteins. J Biol Chem 2003; 278: 3293-3297.
9. Bouschet T, Martin S, Henley JM. Receptor-activitymodifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. J Cell Sci 2005; 118: 4709-4720.
10. Wootten D, Lindmark H, Kadmiel M et al. Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function. Brit J Pharmacol 2013; 168: 822-834.
11. Lenhart PM, Broselid S, Barrick CJ, Leeb-Lundberg LM, Caron KM. G-protein-coupled receptor 30 interacts with receptor activity-modifying protein 3 and confers sex-dependent cardioprotection. J Mol Endocrinol 2013; 51: 191-202.
12. Weston C, Lu J, Li N et al. Modulation of glucagon receptor pharmacology by receptor activity-modifying protein-2 (RAMP2). J Biol Chem 2015; 290: 23009-23022.
13. Hollenstein K, de Graaf C, Bortolato A et al. Insights into the structure of class B GPCRs. Trends Pharmacol Sci 2014; 35: 12-22.
14. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev 2015; 67: 564-600.
15. Walker CS, Eftekhari S, Bower RL et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol 2015; 2: 595-608.
16. Booe JM, Walker CS, Barwell J et al. Structural basis for receptor activity-modifying protein-dependent selective peptide recognition by a G protein-coupled receptor. Mol Cell 2015; 58: 1040-1052.
17. Parthier C, Kleinschmidt M, Neumann P et al. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci USA 2007; 104: 13942-13947.
18. Pioszak AA, Xu HE. Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc Natl Acad Sci USA 2008; 105: 5034-5039.
19. Pioszak AA, Parker NR, Gardella TJ, Xu HE. Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J Biol Chem 2009; 284: 28382-28391.
20. Runge S, Thogersen H, Madsen K, Lau J, Rudolph R. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 2008; 283: 11340-11347.
21. Underwood CR, Garibay P, Knudsen LB et al. Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J Biol Chem 2010; 285: 723-730.
22. Archbold JK, Flanagan JU, Watkins HA, Gingell JJ, Hay DL. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol Sci 2011; 32: 591-600.
23. Hay DL, Christopoulos G, Christopoulos A, Poyner DR, Sexton PM. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol 2005; 67: 1655-1665.
24. Tilakaratne N, Christopoulos G, Zumpe ET, Foord SM, Sexton PM. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 2000; 294: 61-72.
25. Morfis M, Tilakaratne N, Furness SG et al. Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology 2008; 149: 5423-5431.
26. Manglik A, Kim TH, Masureel M et al. Structural insights into the dynamic process of β2-adrenergic receptor signaling. Cell 2015; 161: 1101-1111.
27. Huang W, Manglik A, Venkatakrishnan AJ et al. Structural insights into μ-opioid receptor activation. Nature 2015; 524: 315-321.
28. Sounier R, Mas C, Steyaert J et al. Propagation of conformational changes during μ-opioid receptor activation. Nature 2015; 524: 375-378.
29. Rasmussen SG, DeVree BT, Zou Y et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011; 477: 549-555.
30. Dror RO, Grren HF, Valant C et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 2013; 503: 295-299.
31. Motlagh HN, Wrabl JO, Li J, Hilser VJ. The ensemble nature of allostery. Nature 2014; 508: 331-339.
32. Haliloglu T, Bahar I. Adaptability of protein structures to enable functional interactions and evolutionary implications. Curr Opin Struct Biol 2015; 35: 17-23.
33. Tsai CJ, Nussinov R. A unified view of 'how allostery works'. PLoS Comput Biol 2014; 10: e1003394.
34. Lee SM, Hay DL, Pioszak AA. Calcitonin and amylin receptor peptide interaction mechanisms: Insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins. J Biol Chem. (e-pub ahead of print 19 February 2016; doi: pii:jbc.M115.713628).
35. Udawela M, Christopoulos G, Tilakaratne N et al. Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. Mol Pharmacol 2006a; 69: 1984-1989.
36. Udawela M, Christopoulos G, Morifs M et al. A critical role for the short intracellular C terminus in receptor activity-modifying protein function. Mol Pharmacol 2006b; 70: 1750-1760.
37. Dickerson IM. Role of CGRP-receptor component protein (RCP) in CLR/RAMP function. Curr Protein Pept Sci 2013; 14: 407-415.
38. Hay DL, Harris PW, Kowalczyk R et al. Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation. Brit J Pharmacol 2014; 171: 415-426.
39. Pham V, Wade JD, Purdue BW, Sexton PM. Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor. J Biol Chem 2004; 279: 6720-6729.
40. Poyner DR, Sexton PM, Marshall I et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002; 54: 233-246.
41. Qi T, Dong M, Watkins HA et al. Receptor activitymodifying protein-dependent impairment of calcitonin receptor splice variant Delta(1-47)hCT((a)) function. Brit J Pharmacol 2013; 168: 644-657.
42. Bailey RJ, Hay DL. Agonist-dependent consequences of proline to alanine substitution in the transmembrane helices of the calcitonin receptor. Brit J Pharmacol 2007; 151: 678-687.
43. Simms J, Hay DL, Bailey RJ et al. Structure-function analysis of RAMP1 by alanine mutagenesis. Biochemistry 2009; 48: 198-205.
44. Gingell JJ, Qi T, Bailey RJ, Hay DL. A key role for tryptophan 84 in receptor activity-modifying protein 1 in the amylin 1 receptor. Peptides 2010; 31: 1400-1404.
45. Poirot O, O'Toole E, Notredame C. Tcoffee@igs: a web server for computing, evaluating and combining multiple sequence alignments. Nucleic Acids Res 2003; 31: 3503-3506.
46. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993; 234: 779-815.
47. Laskowski RA. PDBsum: summaries and analyses of PDB structures. Nucleic Acids Res 2001; 29: 221-222.
48. Li H, Robertson AD, Jensen JH. Very fast empirical prediction and rationalization of protein pKa values. Proteins 2005; 61: 704-721.
49. Dolinsky TJ, Czodrowski P, Li H et al. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 2007; 35: W522-W525.